Want to join the conversation?
$CBM agreed to buy privately-owned PharmaCore, which specializes in developing, manufacturing and scaling up small molecule Active Pharmaceutical Ingredients (APIs) for clinical phase projects, for about $25MM. $CBM expects deal, net of deal fees, to have neutral impact on EPS in 2016 and to be accretive in 2017. The deal will close within 30 days.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.